Trial reportMedicine2017
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial.
Trial report in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Allicin as add-on therapy forWorld journal of gastroenterology · 2019Pooled it
- Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.Journal of digestive diseases · 2022Trial
- A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment.Journal of digestive diseases · 2020Trial
- Alkaloids Mediate Multi-Level Modulation of Gastric Carcinogenesis: From Antibacterial and Anti-Inflammatory Actions to Antitumor Effects.International journal of molecular sciences · 2026Review
- Berberine and Berberine-Derived Compounds as Promising Weapons AgainstPharmaceuticals (Basel, Switzerland) · 2026Review
- Dietary berberine supplementation regulates production performance, antioxidant capacity, and immunity of Wenchang chicken (Gallus gallus domestics).Poultry science · 2026Article
- Berberine Toxicity Profile in Experimental Models as a Basis for Assessing Its Biological Safety.Molecules (Basel, Switzerland) · 2026Article
- Efficacy and safety of Qingwei Zhitong pellets-containing quadruple therapy for eradication: a prospective, single-center, randomized trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Natural products based on Correa's cascade for the treatment of gastric cancer trilogy: Current status and future perspective.Journal of pharmaceutical analysis · 2025Review
- Berberine and its nanoformulations and extracts: potential strategies and future perspectives against multi-drug resistant bacterial infections.Frontiers in microbiology · 2025Review
- Berberine pharmacological properties and therapeutic potential across cancer, digestive, metabolic, cardiovascular, and neurological diseases: an update review.EXCLI journal · 2025Review
- Herbs and their Active Constituents for Gastric Cancer and Related Problems - Preclinical and Clinical Studies.Current protein & peptide science · 2025Review
- The Aging Stomach: Clinical Implications ofInternational journal of molecular sciences · 2024Review
- A specific super-enhancer actuated by berberine regulates EGFR-mediated RAS-RAF1-MEK1/2-ERK1/2 pathway to induce nasopharyngeal carcinoma autophagy.Cellular & molecular biology letters · 2024Article
- Review of Phytochemical Potency as a Natural Anti-Molecules (Basel, Switzerland) · 2023Review
- Focusing onFrontiers in cellular and infection microbiology · 2023Review
- Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro.Viruses · 2021Article
- Berberine Influences the Survival of Fat Grafting by Inhibiting Autophagy and Apoptosis of Human Adipose Derived Mesenchymal Stem Cells.Drug design, development and therapy · 2021Article
- Biological Activity of Berberine-A Summary Update.Toxins · 2020Review
- Biological properties and clinical applications of berberine.Frontiers of medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to increasing antimicrobial resistance, a bismuth-based quadruple regimen has been recommended as an alternative first-line therapy for Helicobacter pylori (H pylori) eradication. However, different results are varied greatly and the availability of bismuth was limited in some countries. We assessed the efficacy and safety of 14-day berberine-containing quadruple therapy as an alternative regimen for H pylori eradication.
methodsIn a randomized, open-label, non-inferiority, phase IV trial between November 25, 2014, and October 15, 2015, 612 treatment-naive patients were randomly assigned to 14-day berberine-containing (n = 308) or 14-day bismuth-containing (n = 304) quadruple therapy. The primary outcomes were eradication rates determined by the C urea breath test (C-UBT) 28 days after the end of treatment. The secondary outcomes were adverse events and compliance.
resultsThe baseline demographic data including age, gender, body mass index (BMI), general condition and severity score were not statistically different in both groups. The eradication rates in bismuth and berberine groups were 86.4% (266/308) and 90.1% (274/304) in intention-to-treat (ITT) analysis (P = .149), and 89.6% (266/297) and 91.3% (273/299) in per-protocol (PP) analysis (P = .470), respectively. No statistically significant difference was found in the overall incidence of adverse events between both groups (35.7% vs 28.6%, P = .060).
conclusionsBoth regimens achieved the recommended efficacy for H pylori eradication. The berberine-containing quadruple regimen was not inferior to bismuth-containing quadruple regimen and can be recommended as an alternative regimen for H pylori eradication in the local region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.